Beckman Coulter, Inc. Access Total T4, REF 33800, IVD, thyroxine reagent assay. Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Access Total T4, REF 33800, IVD, thyroxine reagent assay.
Brand
Beckman Coulter, Inc.
Lot Codes / Batch Numbers
Lot numbers: 338555, exp. 31 JUL 2024, 338556, exp. 31 AUG 2024, 338734, exp. 30 SEP 2024, and 338958, exp. 31 OCT 2024, UDI-DI 15099590225742.
Products Sold
Lot numbers: 338555, exp. 31 JUL 2024; 338556, exp. 31 AUG 2024; 338734, exp. 30 SEP 2024; and 338958, exp. 31 OCT 2024; UDI-DI 15099590225742.
Beckman Coulter, Inc. is recalling Access Total T4, REF 33800, IVD, thyroxine reagent assay. due to Four lots of Access Total T4 reagent lots demonstrated imprecision outside of the 10% specification which may result in erroneous or delayed results.. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Four lots of Access Total T4 reagent lots demonstrated imprecision outside of the 10% specification which may result in erroneous or delayed results.
Recommended Action
Per FDA guidance
The recalling firm issued letters on 2/8/2024 via email and standard postal mail to their U.S. customers and postal mail to their OUS customers. The letter explained the issue, impact, and actions to be taken. The actions included: (1) Discontinue using the affected lots and discard all remaining reagent packs from the lots; (2) The firm recommended performing a retrospective review on patient results generated with the affected reagent lots and assess the need for retesting;(3) Contact the local Beckman Coulter representative for replacement product requests; (4) For customers in the U.S. and Canada, complete the attached Replacement Order Form; and (5) For customers outside the U.S. and Canada, contact their local Beckman Coulter representative. The consignee was requested to share the letter information with their laboratory staff and retain the notification as part of their laboratory Quality System documentation. If the affected product was forwarded to another laboratory, they were requested to provide them a copy of the letter. The consignee was requested to respond within 10 days either electronically via email or manually by completing and returning the enclosed Response Form.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026